How probenecid affects mirdametinib in healthy volunteers
Treatments studied
This study checks how probenecid (a medicine for gout) changes the levels of mirdametinib (an experimental cancer drug) in healthy people. It helps doctors understand dosing and safety before testing in patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a healthy adult aged 18 or older.
- You have a body mass index (BMI) between 18 and 30.
- You have no significant medical conditions, especially heart, eye, or stomach problems.
- You are not pregnant or breastfeeding, and you agree to use birth control if needed.
- You are willing to avoid certain foods, drinks, and medications during the study.
- You have not used tobacco, alcohol, or recreational drugs recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a new experimental drug (M5542) in healthy volunteers to see how safe it is and how the body processes a single dose. If you are in good health and meet simple weight and medical history criteria, you may be able to join.
This study looks at how mirdametinib is processed in people with liver problems compared to healthy people. It will help doctors understand if the dose needs to be adjusted.
This study tests how the body processes the experimental medicine PF-07328948 in people with different levels of kidney function. It may help find the right dose for people with kidney disease.
This trial tests a drug called mirdametinib for people with specific types of brain tumors or neurohistiocytosis (a rare condition affecting the nervous system). The drug targets mutations that cause these conditions to grow.
This Phase 1/2 study tests mirdametinib, a targeted medicine, in children and young adults with low-grade glioma (a slower-growing brain tumor). It aims to find the best dose and see how well the treatment works, especially for tumors with certain “MAPK pathway” changes.
This trial tests an experimental oral drug called mirdametinib for people with advanced melanoma that has a specific gene change (NF1 mutation). To join, you must have already had immunotherapy, but not a MEK/ERK/RAF targeted drug before.
Hear when a new Healthy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.